Biopharma Insights This protocol studies the role of chemokine (C-C motif) ligand 5 (CCL5) in the hypothalamus by delivering an antagonist, MetCCL5, into the mouse brain using a micro-osmotic pump brain infusion system. This transient inhibition of CCL5 activity interrupted hypothalamic insulin signaling, leading to glucose intolerance and peripheral systemic insulin sensitivity.
Total time
~2 hrs/surgery + 1 week recovery + 3 hrs testing
Model organism
Mouse C57BL/6J
Steps
1
Prepare micro-osmotic pump infusion systems
Assemble and fill micro-osmotic pumps with MetCCL5 antagonist or vehicle for continuous brain infusion.
▶ 01:21
2
Implant micro-osmotic pump intracerebroventricularly
Perform stereotaxic surgery to cannulate the lateral ventricle and implant the pump subcutaneously.
▶ 02:41
3
Perform OGTT and ITT
Administer oral glucose or intraperitoneal insulin and measure blood glucose over time.
▶ 04:15
4
Analyze glucose metabolism and insulin signaling
Assess glucose tolerance, insulin sensitivity, and hypothalamic insulin signal activation.
▶ 06:04
5
Conclude hypothalamic CCL5 role in glucose homeostasis
Summarize how transient CCL5 inhibition impairs hypothalamic insulin signaling and peripheral glucose tolerance.
▶ 07:27